Casdozokitug, in combination with atezolizumab/bevacizumab, final data demonstrate durability of response and improvement in depth of response including a 17.2% complete response rate – – Antitumor ...
The study highlights T2-low and T17-high asthma endotypes in minoritized youths, offering insights for precision medicine and improved asthma management.